Clinical Trial Update: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of RO4929097, a gamma-secretase/Notch signaling pathway inhibitor, in stage IV melanoma was terminated. Results from the study were posted on 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2016-06-14